Globus Medical lifts full-year EPS view as Q2 revenue climbs 5.9% and non-GAAP EPS jumps 55.8%

summarizeSummary

Globus Medical posted Q2 2026 revenue of $789.6M (+5.9% YoY) and non-GAAP diluted EPS of $1.34 (+55.8% YoY). Full-year non-GAAP EPS guidance was raised to $4.95–$5.05, while revenue guidance was reaffirmed.

check_boxKey Events · Earnings and Guidance · GMED

• Q2 Revenue +5.9% to $789.6M

  Worldwide net sales rose 5.9% (5.6% constant currency) to $789.6 million, led by US Spine growth of 7% and International Spine growth of 14% as-reported.

• Non-GAAP EPS Surges 55.8%

  Non-GAAP diluted EPS reached $1.34, up from $0.86 a year ago, driven by gross margin expansion of 200 bps and operating leverage. GAAP EPS of $1.10 reflects a prior-year bargain purchase gain, not operational decline.

• Full-Year EPS Guidance Raised

  Management raised 2026 non-GAAP diluted EPS guidance to $4.95–$5.05 from $4.70–$4.80, while reaffirming revenue guidance of $3.18–$3.22 billion.

• Strong Cash Flow and Balance Sheet

  Free cash flow for the first half of 2026 was $339.3 million, up from $172.5 million a year ago. Cash and marketable securities totaled $840.5 million at quarter-end.

auto_awesomeAnalysis · GMED · Industrial Applications And Services

A strong second quarter saw revenue advance 5.9% to $789.6 million, fueled by share gains in US Spine and expanding international reach. Non-GAAP diluted EPS soared 55.8% to $1.34, underscoring margin expansion and operating leverage. The GAAP EPS figure of $1.10 reflects a non-cash artifact—a prior-year bargain purchase gain from the Nevro acquisition—rather than any operational softness. Bolstered by this momentum, management raised full-year non-GAAP EPS guidance to $4.95–$5.05, signaling confidence in sustained earnings growth.